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Abstract: Hereditary hemorrhagic telangiectasia (HHT), also known by the eponym 
Osler–Weber–Rendu syndrome, is a group of related disorders inherited in an autosomal domi-
nant fashion and characterized by the development of arteriovenous malformations (AVM) in the 
skin, mucous membranes, and/or internal organs such as brain, lungs, and liver. Its prevalence 
is currently estimated at one in 5,000 to 8,000. Most cases are due to mutations in the endoglin 
(HHT1) or ACVRLK1 (HHT2) genes. Telangiectasias in nasal and gastrointestinal mucosa gener-
ally present with recurrent/chronic bleeding and iron deficiency anemia. Larger AVMs occur in 
lungs (∼40%–60% of affected individuals), liver (∼40%–70%), brain (∼10%), and spine (∼1%). 
Due to the devastating and potentially fatal complications of some of these lesions (for example, 
strokes and brain abscesses with pulmonary AVMs), presymptomatic screening and treatment 
are of utmost importance. However, due to the rarity of this condition, many providers lack 
an appreciation for the whole gamut of its manifestations and complications, age-dependent 
penetrance, and marked intrafamilial variation. As a result, HHT remains frequently underdiag-
nosed and many families do not receive the appropriate screening and treatments. This article 
provides an overview of the clinical features of HHT, discusses the clinical and genetic diagnostic 
strategies, and presents an up-to-date review of literature and detailed considerations regarding 
screening for visceral AVMs, preventive modalities, and treatment options.
Keywords: arteriovenous malformations, epistaxis, bevacizumab, embolization, guidelines, 
screening, review
Introduction
Hereditary hemorrhagic telangiectasia (HHT), also known by the eponym Osler–
Weber–Rendu disease is a group of autosomal dominant disorders characterized 
by presence of multiple arteriovenous malformations (AVMs) in the skin, mucous 
membranes, and frequently internal organs such as lungs, liver, and brain. Current 
prevalence is estimated between one in 5,000 to 8,000. While this is thought to affect 
people of all races in all parts of the world, higher prevalence has been reported in 
specific populations, for example, one in 1,330 in Afro-Caribbean residents of Curaçao 
and Bonaire.1–3
AVMs in HHT are characterized by lack of intervening capillaries between arter-
ies and veins. Small AVMs known as telangiectasias are pink to red lesions, typically 
0.5–1.0 mm in diameter. They may occur anywhere in the body but are most apparent 
on the lips, tongue, face, fingertips, and the nasal, buccal, and gastrointestinal (GI) 
mucosa. Unlike petechiae, which have a similar appearance, they blanch with pres-
sure and refill immediately after the pressure is released. Due to their thin walls and Journal of Blood Medicine 2014:5 submit your manuscript | www.dovepress.com
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proximity to the skin or mucosal surfaces, they are prone 
to rupture and bleeding with minimal injury. Epistaxis and 
mucocutaneous telangiectasias are the most common clinical 
manifestations.3,4 HHT is also often complicated by the pres-
ence of larger AVMs, also referred to as arteriovenous shunts 
or fistulae. These can be up to several centimeters in size and 
are most frequently observed in the lungs, liver, and brain. 
While these can rupture, complications from these larger 
AVMs are more often a result of shunting of blood. Involve-
ment of systemic vasculature, for example in the liver, leads to 
a high cardiac output state. Pulmonary AVMs (PAVMs) serve 
as right-to-left shunts that lead to hypoxemia or neurologic 
sequelae due to paradoxical embolism of cruoric or septic 
thrombi. It should be noted that these vascular malformations 
can occur in disorders besides HHT, in isolation, and as part 
of another syndrome, and their presence is not adequate to 
arrive at this diagnosis.
Since HHT affects multiple organ systems, it does not 
“belong to” any one subspecialty; a wide range of physicians 
from medical, surgical, primary care, or emergency medicine 
disciplines may encounter affected patients. Given the rarity of 
this condition, physicians may lack appreciation of its full range 
of manifestations and complications, resulting in missed diag-
noses or significant delays before the diagnosis is established.5,6 
Furthermore, due to the catastrophic nature of some of the 
lesions seen in this syndrome (for example, strokes and 
cerebral abscesses from pulmonary AVMs), screening in the 
presymptomatic phase is extremely important. However, many 
patients and families remain unaware of their diagnosis and do 
not receive appropriate screening and preventive treatment.7 
To bridge these gaps in care for patients with HHT and their 
families, a group of international experts met in Canada in 2006 
and formulated the “International Guidelines for Diagnosis and 
Management of HHT” that were published in 2011.8
Here, we provide a brief overview of the clinical manifes-
tations in HHT, an up-to-date review of diagnostic criteria for 
HHT, guidelines regarding screening in asymptomatic sub-
jects with definite or likely HHT, and optimal management of 
various complications. We will also discuss the literature that 
has become available since October 2006, when the guide-
lines for HHT were initially formulated. In particular, there 
has been much enthusiasm around the use of the vascular 
endothelial growth factor (VEGF) antagonist bevacizumab; 
it has been shown to decrease severity of epistaxis as well 
as reduce liver size and cardiac output in patients with large 
hepatic AVMs (HAVMs). Lastly, we will discuss the impli-
cations of this diagnosis in special circumstances, such as 
pregnancy and when anticoagulation is required.
Clinical overview
Age-related penetrance is observed in HHT. Manifestations 
are rarely present at birth, but develop and worsen with 
increasing age. Individual signs and symptoms are discussed 
below.
epistaxis
Nasal bleeding is the clinical characteristic that most com-
monly brings patients with HHT to medical attention. In a 
series of 324 patients with HHT, epistaxis was reported by 
96% with over half experiencing this symptom before the age 
of 20 years.4 In another survey of 73 patients, 93% reported 
epistaxis, with onset before the age of 10 years in over 50% 
and before the age of 20 years in over 90%; the mean fre-
quency of nosebleeds was 18 per month.9 It is an early and 
clinically evident marker of disease. Occasionally, it can lead 
to chronic anemia and transfusion dependence.
Mucocutaneous telangiectasias
Telangiectasias typically seen on the lips, tongue, buccal 
mucosa, and fingertips have been reported in 75%–90% of the 
affected individuals.4,10 They are usually recognized at a much 
later age than epistaxis, likely due to the relatively subtle and 
nonspecific nature of these lesions. They rarely bleed and the 
main concern is usually cosmetic. There are rare case reports 
of vocal cord involvement manifesting as dysphonia.11
Gastrointestinal bleeding
Although 75% of the patients have gastric or small intestinal 
telangiectasias on endoscopy or capsule examination, only 
one-third eventually suffer from GI bleeding, usually after 
40 years of age.4,12–14 Telangiectasias can occur throughout the 
GI tract, but are almost always more common in the stomach 
and duodenum. Bleeding is often slow and chronic, and may 
be clinically silent with no obvious melena. Symptoms may 
be completely absent until anemia develops. Larger AVMs 
or aneurysms are less commonly observed.
Pulmonary AvMs
PAVMs are more common in the general population than 
previously appreciated. Small pulmonary shunts are evident 
on transthoracic contrast echocardiography (TTCE) in 6%–7% 
of the individuals without HHT.15,16 In a recent study from 
Japan, PAVMs were identified in eight patients (0.038%) 
among 21,235 patients who underwent low-dose computed 
tomography (CT) screening for lung cancer.17 While only 
two patients were diagnosed with HHT in this series, other 
studies have shown that approximately 80%–90% of the Journal of Blood Medicine 2014:5 submit your manuscript | www.dovepress.com
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patients with PAVMs have underlying HHT.18,19 On the other 
hand, depending on the imaging technique used, PAVMs are 
identified in 40%–60% of patients with an underlying diag-
nosis of HHT.20,21
PAVMs can lead to symptoms by causing complications 
such as systemic hypoxemia, pulmonary embolism, high 
output heart failure, or pulmonary hypertension. Symptoms 
may also manifest as a result of PAVM rupture. Dyspnea 
(that is sometimes noticeable only with exertion) is the 
most common symptom attributable to hypoxemia resulting 
from right-to-left shunting of blood, especially if the PAVMs 
are large, multiple, or bilateral.22,23 This, over time may 
lead to clubbing and compensatory polycythemia.24 Acute 
postural change to standing can increase shunting of blood 
through PAVMs located at the base of the lung, resulting in 
orthodeoxia. In a series of 257 patients with PAVMs, 29% 
demonstrated a fall in blood oxygen saturation of at least 
2% with standing.25 Although platypnea accompanying this 
orthodeoxia has been reported in the literature, none of the 
patients in this large series reported dyspnea with standing.26 
Positional oximetry, although not very sensitive, is highly 
specific for PAVMs and should be a part of initial evaluation 
in patients with definite or suspected HHT.25,27 Additionally, 
due to lack of a capillary filter between arterial and venous 
beds, these patients are at risk for paradoxical embolism of 
de novo in situ cruoric thrombi or cruoric thrombi/septic 
thrombi/air emboli developing upstream. These result in 
embolic cerebral events, including embolic strokes and 
cerebral abscesses. In one series of 76 patients undergoing 
embolotherapy, symptomatic strokes were reported in 18%, 
transient ischemic attacks in 37%, and brain abscesses in 
9%.28 Notably, CT imaging of 59 patients in this series 
showed unequivocal evidence of stroke in 36%; cerebral 
AVMs (CAVMs) were documented in only 5%. Morbidity 
and mortality attributable to these catastrophic events is 
significant, hence the need for early screening and timely 
interventions (for example, embolization of PAVMs and 
antibiotic prophylaxis prior to dental procedures). Further-
more, high cardiac output state resulting from right-to-left 
shunting can over time lead to heart failure and/or pulmo-
nary hypertension. According to a study of 1,143 patients 
undergoing PAVM embolization, the mean pulmonary 
arterial pressure was .20 mmHg in 9% of the patients and 
.25 mmHg in 6%.29 Lastly, PAVM rupture can result as a 
complication of pregnancy, pulmonary hypertension, or in 
the presence of high-pressure systemic blood supply via 
bronchial circulation; this may present as hemoptysis and/
or hemothorax.30–33
Migraines are remarkably frequent in HHT patients with 
PAVMs, and there is evidence to suggest that embolization of 
PAVMs leads to symptom improvement.34–36 This association 
may be explained by passage of microthrombi and/or vasoac-
tive substances (eg, serotonin) from the venous system to the 
cerebral circulation via PAVMs, or systemic hypoxemia.37 
That being said, migraines are still more common in HHT 
patients without PAVMs than in the general population.38 
A recent study by Elphick and Shovlin identified an especially 
strong association between epistaxis and migraines in HHT, 
suggesting common pathophysiologic mechanisms underly-
ing both these manifestations.39
CAvMs
CAVMs affect approximately 10% of HHT patients.40–43 
These include, in order of decreasing size, arteriovenous 
fistulae, classical nidal AVMs, micro-AVMs (,1 cm), and 
telangiectasias. Due to the potentially devastating effects 
of cerebral hemorrhage, symptoms suggestive of CAVMs 
should be investigated with magnetic resonance imaging 
(MRI). However, most CAVMs never bleed and compli-
cations associated with currently available diagnostic 
modalities are substantial. Furthermore, recent evidence 
for patients with sporadic CAVMs suggests that the risk of 
stroke or death with interventional management is signifi-
cantly higher than with medical management.44 As such, 
the screening strategy needs to be individualized for each 
patient after careful discussion. It should be emphasized 
that most neurological events in HHT are a consequence 
of paradoxical embolism of clots and bacteria via PAVMs 
to the central nervous system, and CAVMs are detected 
in a small minority of the patients with definite evidence 
of stroke on CT imaging.28
In infants and young children, large-caliber high-flow 
fistulae are more common and may present with intracranial 
bleeds, hydrocephalus, epilepsy, cognitive deficits, or high-
output cardiac failure.41,45–49 Spinal AVMs are substantially 
less frequent (affect 1%–2% of the HHT population), and 
usually present early in childhood with paralysis and/or 
complaint of back pain.45,50,51
HAvMs
Hepatic involvement is reported in up to three-quarters of 
patients with HHT, depending on the imaging technique used. 
In one series of 70 patients, HAVMs were detected in 74% 
using helical CT imaging; these led to symptoms in only 8% 
of these patients.52 In another series using ultrasonography, 
only 41% of the individuals with HHT were found to have Journal of Blood Medicine 2014:5 submit your manuscript | www.dovepress.com
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HAVMs.53 In a study of 154 patients with HHT and HAVMs 
followed over a median period of 44 months, one-quarter 
experienced complications related to these AVMs and 5% 
died from their complications.54
The vascular supply of the liver is unique. Blood enters 
through the hepatic artery and portal vein, combines in the 
hepatic sinusoids and exits via the hepatic veins. Clinical 
manifestations depend on the direction of shunts. The most 
common presentation related to HAVMs in HHT is a hyper-
dynamic circulatory state resulting from left-to-right shunting 
from the hepatic artery or portal vein to the hepatic veins.55 
Hepatomegaly and hepatic bruits may be appreciable on 
physical examination. These, over time, can lead to cardiac 
failure often presenting with dyspnea and dependent edema. 
Shunting of blood from the hepatic artery to the portal vein is 
less commonly observed. In this scenario, increased sinusoidal 
blood flow is associated with nodular transformation in the 
liver, also known as “pseudocirrhosis” and “arterialization” 
of the portal vein.56,57 The peribiliary plexus arising from the 
hepatic artery supplies blood to the biliary tree. Shunting of 
blood away from the hepatic artery to hepatic and/or portal 
veins may also cause ischemia of the intrahepatic or extrahe-
patic biliary systems, manifestations of which include severe 
cholestasis, recurrent cholangitis, and biliary strictures.
Juvenile polyposis
Individuals with juvenile polyposis-HHT overlap syndrome 
(JPHT) with mutations in Smad4 gene (see “Molecular 
diagnosis” section) represent 1%–2% of the total HHT 
population. These patients are at increased risk for colorec-
tal cancer and require close surveillance. More recently, 
connective tissue defects such as enlarged aortic root, 
valvular insufficiency, and aortic dissection have been 
described as well.58,59
venous thromboembolism
HHT patients carry a higher risk for venous thromboembolism 
(VTE) as compared to the general population.60 Although the 
precise reason(s) for this are unknown, one recent study of 
609 HHT patients identified an association of deficient iron 
stores with high coagulation factor VIII levels and increased 
thromboembolic risk.61 Given the predisposition for bleeding, 
anticoagulation presents an obvious challenge in this group 
and is discussed separately in detail.62
immunological abnormalities
In a retrospective analysis of 353 patients with HHT, 13.6% 
were identified to have severe infections.63 Cerebral infections 
accounted for one-third of all infections and were associated 
with the presence of PAVMs. The remaining two-thirds were 
extracerebral, most involved Staphylococcus aureus, and were 
attributed to epistaxis and need for prolonged nasal packing. 
In addition to these mechanical factors, defects in adaptive 
immunity (such as T cell and NK cell lymphopenia, increased 
levels of immunoglobulins G and A, and low levels of immu-
noglobulin M) have recently been identified in HHT.64
Malignancy risk
A prospective study in patients with over 20 years of 
follow-up reported increased mortality attributable to 
complications of HHT in patients younger than 60 years; 
however, mortality in individuals older than 60 years was not 
increased.2 Hosman et al evaluated this discrepancy and found 
that certain malignancies with especially poor prognosis, such 
as lung and liver cancers are less prevalent in HHT and could 
account for the better than expected life expectancy in older 
individuals within this population. Additionally, a modest 
increase in breast cancer prevalence was found, possibly 
related to recurrent exposure to ionizing radiation with CT 
and angiographic studies.65
Diagnostic approaches
Clinical diagnosis
Establishing a diagnosis of HHT is imperative for patients 
and their family members for them to receive the appropri-
ate screening and preventive treatments. This diagnosis has 
conventionally been based on clinical grounds. Consensus 
clinical diagnostic criteria known as Curaçao criteria were 
published in 2000; they remain the mainstay of clinical 
diagnosis to date (Table 1).66
van Gent et al recently demonstrated excellent   diagnostic 
performance for these criteria in 263 first-degree relatives of 
Table 1 Curaçao criteria for clinical diagnosis of HHT
Criteria
  epistaxis Spontaneous and recurrent
  Telangiectasia Multiple, at characteristic sites: lips, oral 
cavity, fingers, and nose
  visceral lesions Such as gastrointestinal telangiectasia, or 
pulmonary, hepatic, cerebra, or spinal AvMs
  Family history A first-degree relative with HHT according 
to these criteria
HHT diagnosis is
  Definite if three or more criteria are present
  Possible or suspected if two criteria are present
  Unlikely if fewer than two criteria are present
Abbreviations: AvM, arteriovenous malformations; HHT, hereditary hemorrhagic 
telangiectasia.Journal of Blood Medicine 2014:5 submit your manuscript | www.dovepress.com
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disease-causing mutation carriers.67 Among the 186 relatives 
with family-specific mutations, clinical diagnosis was 
“definite”, “possible”, and “unlikely” in 160 (90.3%), 
17 (9.1%), and one (0.5%), respectively. Among the remain-
ing 77 family members lacking the mutation, clinical diagno-
sis was definite, possible, and unlikely in zero, 35 (45.5%), 
and 42 (54.5%), respectively. As such, the positive predictive 
value of a definite diagnosis was 100% and the negative 
predictive value of an unlikely diagnosis was 97.7%. A few 
notes of caution regarding employment of these criteria 
are worth mentioning. First, as highlighted by Govani and 
Shovlin, they can prove inadequate when members of a 
family with HHT are encountered. In an individual with 
positive family history and confirmed PAVM(s), the diag-
nosis of HHT is effectively confirmed, even though these 
criteria label the diagnosis as “possible” or “suspected”.68 
At the same time, these criteria do not specify what counts 
as a PAVM. Using chest CT as the reference, TTCE (which 
is now recommended as the first-line examination for PAVM 
screening) has excellent sensitivity and negative predictive 
value, but lacks specificity and positive predictive value for 
detection of PAVMs.15,69 Velthuis et al evaluated the utility 
of TTCE results in establishing the diagnosis of HHT. They 
showed that addition of any pulmonary shunt on TTCE to 
the current Curaçao criteria resulted in increased sensitivity 
from 88% to 94%, but decreased specificity from 74% to 
70%. Excluding grade 1 on TTCE as a diagnostic criterion 
for HHT enhanced the sensitivity to 90%, with no decrease 
in specificity.15 Secondly, as clinical manifestations of HHT 
develop with age, these criteria lack sensitivity and have lim-
ited value in children and young adults with positive family 
history but no other clinical manifestations. Genetic testing is 
required in these cases (see “Molecular diagnosis”). As com-
mented upon in the “International Guidelines for Diagnosis 
and Management of HHT”, these criteria are particularly 
helpful in two situations:8 1) discriminating affected from 
non-affected older adults and 2) ruling in the diagnosis in 
younger adults and children.
Molecular diagnosis
HHT follows an autosomal dominant pattern of inheritance; 
sporadic mutations leading to this syndrome are rare. Based 
on underlying genetic defects, five different types of HHT 
have been described thus far:
1.  HHT type 1 results from mutations in the endoglin gene 
(ENG, HHT1; OMIM#187300).
2.  HHT type 2 results from mutations in the activin receptor-
like kinase 1 gene (ACVRLK1, HHT2; OMIM 600376).
Four hundred and seventy variants in ENG and 375 
variants in ACVRLK1 have been described thus far; these 
account for approximately 87% of the cases.70
3.  JPHT: If testing for ENG and ACVRLK1 is negative, 
sequencing of Smad4 gene (SMAD4, MADH4; OMIM 
175050) identifies mutations in an additional 1%–2% of 
individuals.71–75
These three genes code for proteins in the trans-
forming growth factor-beta (TGF-β) signaling pathway. 
The exact mechanisms by which these genetic defects 
influence the process of angiogenesis are not clear; they 
likely disturb the balance between proangiogenic and 
antiangiogenic signals in the blood vessels, in favor of 
the former. As a result, normal angiogenic stimuli lead to 
the development of AVMs with increasing age.
4.  HHT type 3 is associated with mutations in locus 5q31.3-
q32 (OMIM%601101).76
5.  HHT type 4 is linked to mutations at location 7p14 
(OMIM%610655).77
Specific genes at these two loci have not yet been 
identified, and the mechanisms by which they lead to 
HHT are not known.
6.	 More recently, mutations in the growth differentiation 
factor 2 gene (GDR-2, BMP-9, HHT5; OMIM 615506) 
that are involved in angiogenesis were described in three 
individuals with a vascular-anomaly syndrome that has 
phenotypic similarities with HHT.78
For patients with “definite” clinical diagnosis, genetic test-
ing is not required to confirm their diagnosis. The objective of 
genetic testing is often to identify the specific mutation in the 
index case. Once this family specific mutation is identified, 
targeted sequencing can be valuable in two settings: 1) to 
effectively establish the diagnosis in relatives of individuals 
with HHT who do not (yet) meet clinical diagnostic criteria, 
particularly in children and young adults, and 2) more com-
monly, to rule out the diagnosis in a branch of the family.
A directory of laboratories across the world that offer 
genetic testing for HHT is available on the HHT Foundation 
International website.79 A few caveats about diagnostic usage 
of genetic testing are noteworthy:
•	 Mutations have not been identified in 15%–20% of HHT 
families.80–82 In the appropriate clinical context, negative 
testing in the index patient does not change his/her diag-
nosis and management. However, this does limit being 
able to use targeted genetic testing to rule in or rule out 
the diagnosis in other family members.8
•	 Ten to twenty percent of the families have genetic variants 
(usually potential missense mutations), pathogenicity of Journal of Blood Medicine 2014:5 submit your manuscript | www.dovepress.com
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which are not clear; this can lead to overdiagnosis. This 
will likely become an even bigger problem as newer 
sequencing technologies are applied to promoter and 
intronic sequences of HHT genes.80,83,84
•	 PAVMs and CAVMs are more common in HHT 
type 1, HAVMs and pulmonary arterial hypertension are 
observed more often in HHT type 2, and most studies 
have showed no significant differences in the prevalence 
of GI bleeding between the two HHT types.10,80,85–90 
Nevertheless, all of these features are seen in both 
types. Knowing the underlying mutation does not alter 
the screening or management strategy for an individual 
patient. The only exception to this is patients with JPHT; 
they require regular colonic surveillance for GI malignan-
cies beginning at an early age.74,75,91
Management
In a patient with “possible” and “definite” HHT, optimal 
management includes: 1) treatment directed towards organ-
specific signs and symptoms; 2) screening and subsequent 
management of PAVMs and sometimes CAVMs while in 
the asymptomatic phase, given the disastrous and potentially 
fatal complications associated with them; and 3) education, 
with opportunity for genetic testing in index patients and in 
at-risk family members, whenever possible (see “Molecular 
diagnosis”). It should be noted that most of the current guid-
ing principles are based on expert opinion, there are very few 
randomized controlled trials addressing different therapies 
in HHT.8
epistaxis
Severe epistaxis has been repeatedly found to be the most 
significant clinical variable associated with poor quality of 
life among HHT patients.92–94 Treatment can be difficult and 
frustrating, both for the patient and providers. Modus ope-
randi for these patients should include systematic evaluation 
of severity of nosebleeds, a stepwise treatment approach 
(including correction of anemia and iron deficiency), 
and regular follow-up. Hoag at al described a statistically 
validated epistaxis severity score (ESS) that can serve as a 
useful adjunct in clinical evaluation and follow-up of HHT 
patients.95 Given the unique characteristics of this disorder 
and nuances of its management, referral to an otorhinolaryn-
gologist with expertise in HHT-related epistaxis, whenever 
possible, is recommended. A list of HHT treatment centers 
is available online at the HHT Foundation’s website (http://
www.hht.org/living-with-hht/treatment-centers-2/). Various 
treatment options are discussed next:
•	 Air humidification and regular application of lubricants 
such as saline (to prevent crusting over nasal mucosa) and 
avoidance of injury to nasal mucosa (for example, with 
picking and blowing hard) are generally recommended 
for management of chronic and recurrent nosebleeds.96 
Certain dietary ingredients have been reported to exacer-
bate nosebleeds; these include foods with high salicylate 
content (such as red wine, spices, chocolate, and coffee), 
with natural antiplatelet activity (such as ginger, garlic, 
ginkgo biloba, and ginseng), and with high levels of 
omega-3 acids (such as salmon).39,96 Identification of 
patient-specific triggers and their avoidance may aid with 
epistaxis management.
•	 Surgical options:
○	 Nasal packing is often the first-line of management for 
acute bleeding. Use of pneumatic packing minimizes 
re-bleeding after removal of packing material.
○	 Laser coagulation is recommended as a low-risk 
intervention for management of mild-to-moderate 
epistaxis.97,98 This is considered to be preferable to 
electrical and chemical cautery as it causes less dam-
age to nasal mucosa, which would further worsen 
bleeding.
○	 For severe epistaxis that does not respond to repeated 
endonasal coagulation, septal dermoplasty has been 
shown to be effective in reducing transfusion require-
ments and improving quality of life measures.99 
Alternatively, Young’s nasal closure procedure 
(in which the nostrils are sewn closed so a person 
no longer breathes through the nose) usually leads to 
complete cessation of bleeding; patient often report side 
effects of chronic mouth breathing including altera-
tions in smell and taste senses.100,101 In a recent series 
of 43 patients undergoing this procedure, nosebleeds 
stopped completely in 83% of the patients and a mean 
increase in hemoglobin of 4.68 g/dL was observed.102
○	 Nasal arterial embolization is effective only in the 
short term, as surrounding blood vessels enlarge 
and lead to recurrence of bleeding. This should 
be reserved only for emergent management only, 
until more durable therapies can be started.
○	 Submucosal radiofrequency has recently been shown 
to be safe and efficacious as a therapy for epistaxis 
in HHT, although long-term effects remain to be 
evaluated.103
•	 Medical options: Various medical treatments (antiangio-
genic, hormonal, and antifibrinolytic) have been reported 
for management of HHT-related epistaxis.Journal of Blood Medicine 2014:5 submit your manuscript | www.dovepress.com
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○	 Angiogenesis inhibitors: VEGF levels have been shown 
to be about 15-fold elevated in patients with HHT and 
are implicated in its pathogenesis.104 Bevacizumab is 
a recombinant humanized monoclonal antibody that 
binds to VEGF receptors on endothelial cells and serves 
as a competitive antagonist. In HHT, its systemic admin-
istration has been shown to improve HAVM-related 
symptoms as well as epistaxis.105 Several uncontrolled 
series reported efficacy and safety of local administra-
tion of bevacizumab in HHT-related epistaxis.106–111 
In one recent double-blind, placebo-controlled trial, 
15 adult HHT patients with a minimum of two epistaxis 
episodes per week were randomized to a single intra-
nasal submucosal injection of 100 mg bevacizumab 
or placebo.112 The average daily posttreatment visual 
analog score decreased by 27% in the bevacizumab 
group and by only 3% in the placebo group (P=0.57). 
In another Phase I, randomized, double-blind, placebo-
controlled study (ELLIPSE trial) of 40 patients, five 
increasing doses (12.5, 25, 50, 75, and 100 mg) of 
bevacizumab nasal spray were evaluated.113 The drug 
was well-tolerated in all patients and was not detected 
in their serum; however, no efficacy was observed at 
any dose. A Phase II study is needed to determine the 
effectiveness of the drug. In summary, bevacizumab 
represents a promising therapy for management of 
HHT-related epistaxis. The cost and systemic side-effect 
profile of this drug (hypertension, increased bleeding 
risk, increased thromboembolic risk, proteinuria, and 
less frequently, renal thrombotic microangiopathy, 
bowel perforation, and nasal septum perforation) are 
not negligible; however, the adverse effects are largely 
avoided with topical use.
Anecdotal positive reports of thalidomide, another 
antiangiogenic agent have also been presented.114,115 
However, there have been no controlled trials using 
this drug. Additionally, nonselective beta-blockers 
such as propranolol and timolol may have some 
antiangiogenic properties as well (related to vasocon-
striction and reduced VEGF expression). They have 
been documented to be effective in the treatment of 
infantile hemangiomas, and may be a potential thera-
peutic option for HHT in future.116–118
○	 Hormonal and antihormonal therapies: Combined 
estrogen–progesterone at doses used for oral contra-
ception may eliminate bleeding in symptomatic HHT 
and could represent a reasonable option for women 
of childbearing age.119 Similarly, selective estrogen 
receptor modulators such as tamoxifen and ralox-
ifene may have a role in management of HHT-related 
epistaxis in postmenopausal women.120–122 Yaniv et al 
reported a trial where 25 patients with HHT-related 
epistaxis were randomly assigned to receive oral 
tamoxifen 20 mg/day or placebo for 6 months. Among 
the 21 participants who completed the trial, nine out 
of ten tamoxifen-treated patients reported alleviation 
in the frequency and severity of their nosebleeds, as 
opposed to only three out of eleven in the placebo 
arm.121 Beneficial side effects of tamoxifen include 
prevention of bone loss and improvement in serum 
lipid profile. In addition to unpleasant effects resulting 
from its antiestrogenic properties (mood changes, hot 
flashes, etc), the most concerning adverse effect is the 
increased incidence of uterine malignancies.
○	 Antifibrinolytics: A recent randomized, double-blind 
and placebo-controlled trial of tranexamic acid dem-
onstrated a 50% decrease in nosebleeds; however, 
no significant improvement in the primary outcome, 
ie, blood hemoglobin concentration was observed.123 
Aminocaproic acid has also been reported to decrease 
epistaxis severity.124
○	 Antioxidants such as N-acetyl cysteine (NAC) have 
also been evaluated in the treatment of epistaxis. In an 
observational study, 43 patients taking NAC 600 mg 
thrice daily for 12 weeks reported a decrease in the 
frequency and severity of diurnal nosebleeds.125
Gi bleeding and malignancies
Management in these patients usually focuses on early 
detection and treatment of anemia and underlying iron 
deficiency.
Because of increased risk of GI bleeding with age, annual 
measurement of hemoglobin or hematocrit and serum iron 
studies beginning at 35 years of age is recommended.8 Direct 
endoscopic evaluation should be performed only if anemia 
is present and is disproportionate to the amount of epistaxis. 
Fecal occult blood testing can be falsely positive due to swal-
lowed blood from nosebleeds, and hence, is less useful as a 
screening. As noted earlier, based on our current knowledge, 
JPHT represents the only subtype where the screening strategy 
is affected by the underlying genotype. Juvenile polyposis 
in these patients places them at increased risk for colonic 
  malignancies. Screening colonoscopies starting at 15–18 years 
of age or at an age 5 years younger than at which the youngest 
family member developed colon cancer, whichever is earlier, 
and every 2 years thereafter, are recommended.91Journal of Blood Medicine 2014:5 submit your manuscript | www.dovepress.com
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Since most bleeding occurs in the stomach and 
duodenum, an upper esophagogastroduodenoscopy (EGD) 
is usually adequate to make the diagnosis. However, pres-
ence of telangiectasia does not rule out other sources of 
bleeding or anemia (for instance, epistaxis) in these patients. 
If upper and lower endoscopies do not adequately explain 
the severity of findings, or in patients where numerous 
lesions are expected (HHT type 1, older age, or severe 
anemia in the setting of limited epistaxis), video capsule 
endoscopy may be considered as the initial step as it pro-
vides better information about the distal part of the duode-
num and small intestine.89 Iron absorption and handling are 
preserved in HHT, and the iron deficiency is explained by 
the losses due to chronic bleeding.126 Aggressive and long-
term iron replacement is often required for maintenance of 
iron stores and to minimize the need for blood transfusions. 
Oral iron supplements should be attempted before switching 
to intravenous preparations. Evidence for use of different 
medical therapies to reduce chronic GI bleeding (estrogen–
progesterone preparations, danazol, tamoxifen, thalidomide, 
lenalidomide, interferon, sirolimus, and bevacizumab) is 
limited to case reports and small case series.13,124,127–134 There 
is one small double-blind, placebo-controlled, cross-over 
trial of combination hormonal therapy (0.05 mg ethinyl 
estradiol plus 1 mg norethisterone) versus placebo; five of 
the six HHT patients experienced no further GI bleeding.135 
Limited attempts at cauterization of large visible telangi-
ectasias by an experienced endoscopist may be considered; 
however, repeated endoscopic attempts are unlikely to be 
effective.136–138
PAvMs
Neurological complications resulting from PAVMs are a 
significant cause of morbidity and mortality among HHT 
patients.43,139,140 Screening for PAVMs is recommended in all 
patients with possible or definite HHT at the time of initial 
evaluation, regardless of age.8,141
TTCE, also referred to as “bubble echocardiography” is 
recommended as the first step in screening for PAVMs. It 
is simple, minimally invasive, and does not require expo-
sure to radiation. After intravenous injection of agitated 
saline solution, if a right-to-left pulmonary shunt is present, 
echoic microbubbles (referred to as contrast) can be easily 
visualized in the left cardiac cavities after 2–5 seconds 
or three to eight cardiac cycles (appearance of contrast in 
the left ventricle within one cycle of its appearance in the 
right atrium suggests an intracardiac right-to-left shunt). 
Depending on the extent of opacification of the left ventricle, 
a semi-quantitative assessment of the shunt size can be 
obtained.142 These grades are:
1. Grade 0, no bubbles (no additional testing is required);
2. Grade 1, occasional filling with less than 30 bubbles;
3. Grade 3, moderate filling with 30-100 bubbles; and 
4. Grade 4, complete opacification with more than 100 
bubbles.
Multiple prospective studies have documented excel-
lent sensitivity (97%–100%) and negative predictive value 
(99%–100%) of TTCE for detection of PAVMs, making it 
an excellent screening test.16,69 However, it lacks specific-
ity (49%–77%) and the positive predictive value is low 
(32%–51%). Additionally, as noted earlier, a study by 
Velthuis et al showed limited diagnostic significance of 
grade 1 shunts detected by TTCE.15 A recent cross-sectional 
study by the same group that included over 1,000 patients 
with HHT showed that a pulmonary shunt grade 1 was not 
associated with increased prevalence of cerebral complica-
tions (odds ratio [OR]: 0.44; 95% confidence interval [CI]: 
0.05–4.13; P=0.47), whereas pulmonary shunts grade 2 and 
grade 3 carried an OR of 4.78 (95% CI: 1.14–20.0; P=0.03) 
and 10.4 (95% CI: 2.4–45.3; P=0.002), respectively, for 
cerebral ischemic event or brain abscess.143 Another analysis 
demonstrated that among 772 HHT patients, none of the 
201 individuals with grade 1 TTCE results had PAVMs on 
chest CT that were amenable to embolization.144 Based on 
these data and concerns about potential long-term effects of 
repeated exposure to radiation, it appears reasonable to state 
that CT can safely be withheld in asymptomatic individuals 
with grade 1 pulmonary shunt on TTCE.145 On the other hand, 
follow-up imaging is definitely warranted in all patients with 
grade 2 and grade 3 results. Low-dose CT techniques allow 
an approximately 50% reduction in radiation dose without 
any significant difference in detection of abnormalities, 
and should be preferred over standard CT protocols.145 Use 
of magnetic resonance angiography (MRA) has not been 
evaluated for PAVM screening; however, it may have a role 
in preembolization planning.146 Its biggest advantage over 
CT is avoidance of ionizing radiation exposure.
Management of PAVMs is largely interventional. The 
“International Guidelines for Diagnosis and Management of 
HHT” recommended transcatheter embolization for PAVMs 
with feeding artery diameter greater than 2–3 mm.8 In 2008, 
Shovlin et al documented that the risk of cerebral events 
from PAVMs in HHT is independent of the feeding artery 
diameter; their study also demonstrated effectiveness of 
embolization in treating PAVMs in reducing strokes.147 These 
data imply that all PAVMs, where embolization is considered Journal of Blood Medicine 2014:5 submit your manuscript | www.dovepress.com
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technically feasible and safe (irrespective of size), should 
be treated. Once the decision to proceed with embolization 
is made, a conventional diagnostic pulmonary angiogram 
is required to fully characterize the AVM, followed by 
catheter-directed placement of embolic material (such as 
metallic coils, detachable balloons, and Amplatzer vascular 
plugs) into the feeding artery until the blood flow through 
the PAVM stops. Whenever possible, both these steps should 
be done in the same session to minimize total radiation 
exposure. Amplatzer vascular plugs allow better management 
of larger AVMs, complex AVMs, and multiple AVMs in a 
single session and are being increasingly used.148–150 Various 
studies have documented safety and short- and long-term 
effectiveness of the procedure.18,148,149,151–154 Pleuritic chest 
pain, usually self-limited, is the most common complication. 
Recanalization of the occluded feeding artery was identi-
fied as the most common reason for treatment failure, often 
requiring reembolization.154,155 As a result, CT is recom-
mended 3–6 months after the procedure, and then another 
3 years later.155 Recent evidence suggests that MRA may be 
a reasonable alternative to CT for follow-up examinations 
and detection of recanalization.156 Of note, TTCE remains 
positive in ∼90% of the patients despite complete occlusion 
of all angiographically visible PAVMs (likely reflective of 
other smaller PAVMs), and is not helpful in follow-up.157
The role of surgery is limited to management of life-
threatening hemorrhage from a ruptured AVM, when embo-
lization is not available. Lung transplantation is occasionally 
pursued for patients who have diffuse bilateral disease refrac-
tory to all other treatment and are therefore at considerable 
risk for death from their underlying PAVMs.158 There are 
no data regarding efficacy of any pharmacologic options 
discussed earlier in management of PAVMs.
Other measures that should be taken for prevention 
of complications related to PAVMs, treated or untreated, 
include:
1.  Lifelong antibiotic prophylaxis: Strong association 
between oral microorganisms and brain abscesses in 
HHT is well-documented.147 Antibiotic prophylaxis is 
recommended for all patients with PAVMs (treated or 
untreated) prior to procedures with risk of bacteremia, in 
particular dental procedures.159
2.  Careful precautions should be taken in these patients to 
avoid introduction of intravenous air during administra-
tion of intravenous medications.
3.  Avoidance of scuba diving is generally recommended; 
however, the concern regarding increased risk of com-
plications from decompression in patients with PAVMs 
is only theoretical.8 Interestingly, with the exception of 
epistaxis, in-flight complications in patients with HHT 
are relatively uncommon.160
CAvMs
Due to the debilitating and potentially fatal effects of CAVM 
rupture and the lack of evidence regarding effectiveness 
of treatment for asymptomatic CAVMs, the “International 
Guidelines for Diagnosis and Management of HHT” recom-
mended screening for them in all patients (including children 
in the first 6 months of life) with possible or definite HHT.8 
However, this has been a subject of significant debate for 
many reasons. First of all, most CAVMs never bleed. In 
fact, the bleeding risk of CAVMs associated with HHT 
(∼0.5% per year) is much lower than with sporadic CAVMs 
(2%–4% per year).161 However, there remains concern regard-
ing selection bias and survivor bias leading to better CAVM 
rupture rates in HHT. Secondly, the techniques employed for 
establishing the diagnosis carry more than minimal risk. While 
MRI itself poses minimal risk, sedation or anesthesia is often 
required in infants and children undergoing this procedure. 
Diagnostic angiography, which is the gold standard for 
diagnosis and required for treatment planning, is associated 
with a 0.5% risk of permanent stroke.162 Thirdly and most 
importantly, the evidence that has become available since 
2006 when these guidelines were initially prepared suggests 
that the benefits of managing these CAVMs are outweighed 
by the risks of interventional therapies. In the ARUBA trial, 
where 223 patients with non-HHT–related CAVMs were 
randomized to interventional therapy vs medical management 
alone, the risk of stroke or death in the interventional arm was 
three-fold higher (30.7% vs 10.1%), warranting premature 
termination of the study.44 Such studies evaluating the risk–
benefit considerations have not been conducted in the HHT 
population (where the true incidence of CAVM rupture may 
be higher). Considering all these reasons, we suggest that 
instead of routinely screening all asymptomatic individuals 
with definite or possible HHT, the possibility that CAVMs 
will be identified in about 10% of the individuals with HHT 
and the concern that the risks of therapy may outweigh its ben-
efits should be discussed explicitly with the patients and their 
families. The decision to proceed or not proceed with imag-
ing should be made only after careful discussions. History of 
cerebral hemorrhage in a relative may be a considerable source 
of worry for the other family members with HHT. Whether 
the predisposition to cerebral hemorrhage related to CAVM 
is familial or related to a particular genotype is not known; 
however, a negative imaging study may help alleviate their Journal of Blood Medicine 2014:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
200
Garg et al
anxiety. Another scenario where this may be useful is prior 
to making a decision regarding initiation of anticoagulation 
(see “Antiplatelet therapy and anticoagulation”).
When the decision is made to proceed with screening 
or in patients with symptoms suggestive of CAVMs, brain 
MRI with and without contrast is the appropriate initial 
investigation.163–166 Angiography is required for confirmation 
of diagnosis and treatment planning. The size and number 
of lesions, venous drainage pattern, and involvement of 
the eloquent cortex determine the feasibility and risks of 
intervention (most importantly the risk of hemorrhage).167 
Referral to a center with expertise in managing these AVMs 
is recommended. Open microsurgical excision provides the 
best chance for cure. For lesions that are inoperable, ste-
reotactic radiosurgery is another option; however, the cure 
rate is much lower and depends on the size of the AVM.168 
Unlike with PAVMs, embolization alone is rarely effective 
in the management of CAVMs but may be a useful adjunct 
to surgery or radiation therapy.169
HAvMs
Screening for HAVMs in asymptomatic individuals is not 
done routinely, because 1) HAVMs are symptomatic in ,10% 
of the cases; 2) when symptomatic, their presentation is not 
sudden and catastrophic (as with PAVMs and CAVMs); and 
3) usefulness of treatment of asymptomatic lesions is not 
known. That said, screening for HAVMs can be used for clari-
fication of diagnosis in patients meeting one or two Curaçao 
criteria. When screening is undertaken, it is advisable to start 
with Doppler ultrasound.8,170 It is accurate, noninvasive, highly 
available, and inexpensive.52,53,55,71,171–175 Multi-slice CT and 
MRI provide better characterization of hepatic lesions and 
may be considered if expertise in Doppler ultrasound for liver 
AVMs is not available. Mesenteric angiography is almost 
never required. Liver biopsy carries a high risk of hemorrhage 
in these patients and should be avoided.
High-output cardiac failure is treated with conventional 
medical therapy, including correction of anemia (often requir-
ing blood transfusions), salt and fluid restriction, diuretics, 
and beta-blockers. Portal hypertension is managed according 
to present guidelines for cirrhotic patients with salt and fluid 
restriction and diuretics, therapeutic large-volume paracente-
ses with plasma expansion with albumin may be required.
Orthotopic liver transplantation (OLT) offers a definite 
cure.176–178 In the largest series of 40 HHT patients undergoing 
OLT, 17.5% patients died in the early postoperative period 
mainly due to bleeding complications; however, the actuarial 
5- and 10-year survival rates were over 80%.178 Interestingly, 
two of these patients developed multiple recurrent AVMs 
in the graft 8 and 10 years later, possibly due to circulating 
proangiogenic factors. Given the significant risk from sur-
gery and chronic immunosuppression, OLT is reserved for: 
1) intractable heart failure, 2) intractable portal hypertension, 
and 3) ischemic biliary necrosis.8
Hepatic artery embolization frequently improves heart 
failure and portal hypertension; however, the benefit is 
usually transient and the rate of severe complications 
(hepatic necrosis, cholangitis, and cholecystitis) and death 
is extremely high.179–182 As a result, this procedure is limited 
to patients with intractable heart failure or portal hypertension 
who are not candidates for transplantation, after exclusion of 
those at extremely high risk for complications (ie, those with 
cirrhosis, severe biliary disease, or portovenous shunts).183
Systemic bevacizumab is a promising therapeutic option 
for HAVMs. In a recent Phase II trial, 25 adult HHT patients 
with severe liver involvement and a high cardiac index were 
treated with bevacizumab (5 mg/kg every 14 days for a total 
of six injections).105 Six-month follow-up data was available 
for 23 patients; it showed complete response (ie, normal-
ization of cardiac index) in five cases and partial response 
in 15 cases. Blinded cardiac index at 6 months (mean 
4.06 L/min/m2; 95% CI: 3.80–4.33) was significantly lower 
than at the beginning of treatment (mean 5.01 L/min/m2; 
95% CI: 4.72–5.29). Hypertension and proteinuria are com-
mon side effects of this drug. Additionally, VEGF inhibition 
has been implicated in glomerular injury and development 
of a renal thrombotic microangiopathy, requiring withdrawal 
of treatment.184 While OLT remains the therapeutic option of 
choice, bevacizumab may be useful as bridging therapy for 
patients who are awaiting transplantation or an alternative 
for patients who are not eligible for transplantation.
Special considerations
Pregnancy
Pregnancy in HHT is high risk. While a majority of women 
with HHT have an uneventful pregnancy, it is associated with 
an increased risk of life-threatening complications. In a study 
of 484 pregnancies in 199 women, 1.0% resulted in a major 
PAVM bleed, 1.2% in stroke, and 1.0% in maternal death.30 
Screening and management recommendations specific to 
pregnancy include:
•	 Ideally, PAVMs should be screened for and maximally 
treated prior to a planned pregnancy.8
•	 If a woman with HHT who has not had screening for 
PAVMs presents when she is already pregnant, screening 
should still be considered. A small series of seven patients Journal of Blood Medicine 2014:5 submit your manuscript | www.dovepress.com
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showed that transcatheter embolization by an experienced 
interventionalist, with modifications to minimize fetus 
exposure to radiation may be safely undertaken in the 
second and third trimesters.185
•	 In a recent retrospective analysis, no increased risk of 
hemorrhage was found in patients with sporadic CAVMs 
during pregnancy and puerperium.186 Given the low risk 
of bleeds and high risk of any interventional therapy, the 
role of screening (even in women with family history of 
cerebral hemorrhage) is unclear.
•	 Although frequently performed, current evidence does 
not support routine screening in all pregnant women with 
HHT for spinal AVMs prior to administration of epidural 
anesthesia. Spinal AVMs are rare, affecting only 1%–2% 
of the patients and usually present in early childhood.50,51 
In one study, spinal or epidural anesthesia was used in 
92 out of 185 deliveries in women with HHT, none of 
whom had undergone screening for spinal AVMs; no 
complications were observed.187
•	 Parents should be made aware of the 50% likelihood 
of disease in the offspring. There is no evidence for or 
against antenatal testing for HHT at this time.
Antiplatelet therapy and anticoagulation
Patients with HHT (who carry an increased risk for VTE) 
are frequently advised to avoid antiplatelet therapy and 
anticoagulation.62 There are reports where withholding treat-
ment for myocardial infarction due to diagnosis of HHT contrib-
uted to a patient’s death; there are also reports where treatment 
for myocardial infarction led to hemorrhages and worsened 
outcomes.62 While epistaxis worsens with these therapies in 
about 60% of the patients, it is notable that nearly 40% report 
no change in the frequency or severity of nosebleeds.62 The 
side-effect profile with respect to bleeding associated with 
use of antiplatelet and anticoagulant therapies in this popula-
tion is quite variable.188 While data are limited to guide use of 
antiplatelet and anticoagulant therapies in individual patients, 
we want to emphasize that HHT by itself should not be consid-
ered an absolute contraindication. If faced with a compelling 
indication, these medications may be prescribed, at the lowest 
possible doses and with careful monitoring.
Radiation risk
HHT patients, particularly those with PAVMs, are repeatedly 
exposed to ionizing radiation from interventional procedures 
and CTs. In a recent analysis, 246 HHT patients with PAVMs 
underwent 3,309 procedures requiring ionizing radiation 
and cumulative effective dose exceeded 100 mSv (a level 
at which there is considered to be good evidence for risk of 
significant harm) in 11%.145 Physicians need to be cognizant 
of these risks. MRI or low-dose protocols for CTs definitely 
warrant consideration in patients who may be expected to 
undergo multiple procedures over the course of their lifetime, 
especially children.189–191
Summary
Optimal management in HHT comprises:
1.  Early diagnosis: The diagnosis of HHT typically relies 
on clinical findings. Genetic testing is not required to 
confirm the diagnosis in an individual case. However, 
if a family-specific pathogenic mutation is identified, 
it can be used to establish the diagnosis in other family 
members, particularly children and young adults who 
may not meet the clinical diagnostic criteria;
2.  Screening for visceral AVMs: Decisions regarding screen-
ing and treatment of visceral AVMs (especially CAVMs) 
should be made after explicit and careful discussions 
with patients and their families, in view of their age, 
educational level, and cultural background;
3.  Treatment of symptomatic and certain presymptomatic 
lesions such as PAVMs: Our understanding of the efficacy 
and safety of existing therapies in HHT is rapidly evolving 
and many new treatment options are becoming available. 
Whenever appropriate, patients should be encouraged to 
participate in research studies, and;
4.  Education: Effective education and counseling of 
affected individuals regarding the implications of 
diagnosis of “possible” or “definite” HHT and the 
preventive and therapeutic options available for them 
is critical not only for their management, but also for 
identification of at-risk family members. Establish-
ing a diagnosis in them while still in the presymp-
tomatic phase can allow appropriate screening and 
treatment measures to be done in a timely manner.
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